Insider Selling: Twist Bioscience Corporation (NASDAQ:TWST) SVP Sells 292 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 292 shares of Twist Bioscience stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $35.76, for a total value of $10,441.92. Following the completion of the transaction, the senior vice president now owns 127,603 shares in the company, valued at approximately $4,563,083.28. This represents a 0.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Paula Green also recently made the following trade(s):

• On Wednesday, May 21st, Paula Green sold 632 shares of Twist Bioscience stock. The stock was sold at an average price of $29.75, for a total value of $18,802.00.
• On Monday, May 5th, Paula Green sold 1,101 shares of Twist Bioscience stock. The stock was sold at an average price of $37.65, for a total value of $41,452.65.
• On Wednesday, April 2nd, Paula Green sold 140 shares of Twist Bioscience stock. The stock was sold at an average price of $38.73, for a total value of $5,422.20.

Twist Bioscience Trading Up 1.5%

TWST traded up $0.52 during trading on Tuesday, hitting $35.85. The company's stock had a trading volume of 741,258 shares, compared to its average volume of 969,757. Twist Bioscience Corporation has a twelve month low of $27.12 and a twelve month high of $60.90. The company has a quick ratio of 4.24, a current ratio of 4.51 and a debt-to-equity ratio of 0.03. The stock's fifty day moving average price is $33.64 and its 200-day moving average price is $40.86. The firm has a market capitalization of $2.15 billion, a P/E ratio of -11.03 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 54.98% and a negative return on equity of 33.48%. The business had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently modified their holdings of the company. ARK Investment Management LLC grew its holdings in Twist Bioscience by 11.5% during the first quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock worth $245,045,000 after buying an additional 645,730 shares in the last quarter. Vanguard Group Inc. grew its holdings in Twist Bioscience by 1.0% during the first quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock worth $230,356,000 after buying an additional 60,276 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Twist Bioscience by 186.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after buying an additional 1,588,587 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in Twist Bioscience by 54.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock worth $69,972,000 after buying an additional 532,040 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Twist Bioscience by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company's stock worth $63,895,000 after buying an additional 6,908 shares in the last quarter.

Analyst Upgrades and Downgrades

TWST has been the topic of several research reports. JPMorgan Chase & Co. reduced their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Barclays reduced their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. The Goldman Sachs Group reduced their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Guggenheim reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. Finally, Robert W. Baird cut their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.